MRVI vs. MRNA

Last updated Aug 1, 2026

MRVI (Maravai LifeSciences Holdings, Inc.) and MRNA (Moderna, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, MRVI returned -31.63%/yr vs -31.12%/yr for MRNA. Their 0.38 correlation means their historical movements had little consistent relationship.

Performance

MRVI vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Maravai LifeSciences Holdings, Inc. (MRVI) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, MRVI achieves a 102.15% return, which is significantly higher than MRNA's 85.89% return.

MRVI

• 1D: -2.67%
• 1M: 8.77%
• 6M: 95.54%
• YTD: 102.15%
• 1Y: 195.95%
• 3Y*: -15.86%
• 5Y*: -31.63%
• 10Y*: —
• ALL TIME*: -24.26%

MRNA

• 1D: -5.35%
• 1M: -31.27%
• 6M: 24.39%
• YTD: 85.89%
• 1Y: 98.59%
• 3Y*: -21.64%
• 5Y*: -31.12%
• 10Y*: —
• ALL TIME*: 12.68%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
MRNA Moderna, Inc.	$279.32M	$443.27M	$449.57M
MRVI Maravai LifeSciences Holdings, Inc.	$14.10M	$18.27M	$16.79M

MRVI vs. MRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
MRVI Maravai LifeSciences Holdings, Inc.	102.15%	-40.37%	-16.79%	-54.23%	-65.85%	49.38%	-12.21%
MRNA Moderna, Inc.	85.89%	-29.08%	-58.19%	-44.63%	-29.28%	143.11%	12.61%

Correlation

The correlation between MRVI and MRNA is 0.42, which is low. Their historical price movements had little consistent relationship.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.42
Correlation (3Y) Balances recent behavior with more history.	0.40
Correlation (5Y) Shows whether the relationship held over a longer period.	0.40
Correlation (All Time) Calculated using the full available price history since Nov 20, 2020	0.38

Fundamentals

Market Cap MRVI : $1.81B MRNA : $21.75B
EPS MRVI : -$0.72 MRNA : -$8.01
PS Ratio MRVI : 4.67 MRNA : 9.68
PB Ratio MRVI : 4.55 MRNA : 3.21
Total Revenue (TTM) MRVI : $204.73M MRNA : $2.23B
Gross Profit (TTM) MRVI : $59.37M MRNA : -$280.00M
EBITDA (TTM) MRVI : -$118.27M MRNA : -$2.94B

Return for Risk

MRVI vs. MRNA — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

MRVI

MRVI Risk / Return Rank: 95
MRVI Sharpe Ratio Rank: 96
MRVI Sortino Ratio Rank: 94
MRVI Omega Ratio Rank: 92
MRVI Calmar Ratio Rank: 97
MRVI Martin Ratio Rank: 96

MRNA

MRNA Risk / Return Rank: 81
MRNA Sharpe Ratio Rank: 81
MRNA Sortino Ratio Rank: 81
MRNA Omega Ratio Rank: 77
MRNA Calmar Ratio Rank: 84
MRNA Martin Ratio Rank: 84

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

MRVI vs. MRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Maravai LifeSciences Holdings, Inc. (MRVI) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	MRVI	MRNA	Difference
Sharpe ratio: Return per unit of total volatility	2.58	1.25	+1.33
Sortino ratio: Return per unit of downside risk	3.32	2.07	+1.25
Omega ratio: Gain probability vs. loss probability	1.40	1.24	+0.16
Calmar ratio: Return relative to maximum drawdown	6.15	2.53	+3.61
Martin ratio: Return relative to average drawdown	15.22	6.75	+8.47

MRVI vs. MRNA - Sharpe Ratio Comparison

The current MRVI Sharpe Ratio is 2.58, which is higher than the MRNA Sharpe Ratio of 1.25. The chart below compares the historical Sharpe Ratios of MRVI and MRNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

MRVI vs. MRNA - Drawdown Comparison

The maximum MRVI drawdown since its inception was -97.16%, roughly equal to the maximum MRNA drawdown of -95.38%. Use the drawdown chart below to compare losses from any high point for MRVI and MRNA.

Drawdown Indicators

	MRVI	MRNA	Difference
Max Drawdown Largest peak-to-trough decline	-97.16%	-95.38%	-1.78%
Max Drawdown (1Y) Largest decline over 1 year	-29.60%	-33.90%	+4.30%
Max Drawdown (3Y) Largest decline over 3 years	-85.04%	-86.58%	+1.54%
Max Drawdown (5Y) Largest decline over 5 years	-97.16%	-95.38%	-1.78%
Current Drawdown Current decline from peak	-89.16%	-88.68%	-0.48%
Average Drawdown Average peak-to-trough decline	-68.32%	-57.57%	-10.75%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.93%	13.82%	-1.89%

Volatility

MRVI vs. MRNA - Volatility Comparison

The current volatility for Maravai LifeSciences Holdings, Inc. (MRVI) is 14.16%, while Moderna, Inc. (MRNA) has a volatility of 22.40%. This indicates that MRVI experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MRVI	MRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.16%	22.40%	-8.24%
Volatility (6M) Calculated over the trailing 6-month period	41.27%	48.29%	-7.02%
Volatility (1Y) Calculated over the trailing 1-year period	70.65%	69.43%	+1.22%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	74.90%	67.00%	+7.90%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	72.96%	72.39%	+0.57%

Dividends

MRVI vs. MRNA - Dividend Comparison

Neither MRVI nor MRNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both MRVI and MRNA in my portfolio?

MRVI and MRNA have a correlation of 0.42, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, MRVI or MRNA?

MRNA has higher volatility (22.40%) compared to MRVI (14.16%). In terms of maximum drawdown, MRVI dropped -97.16% vs MRNA's -95.38%.

Which has better risk-adjusted returns?

MRVI currently has the higher Sharpe Ratio (2.58 vs 1.25), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.